The development of tissue fibrosis is complex and at the present time, not fully understood. Fibrosis, neurodegeneration and cerebral angiomatosis (FINCA disease) have been described in patients with mutations in NHL repeat-containing protein 2 (NHLRC2). However, the molecular functions of NHLRC2 are uncharacterized. Herein, we identified putative interacting partners for NHLRC2 using proximity-labeling mass spectrometry. We also investigated the function of NHLRC2 using immortalized cells cultured from skin biopsies of FINCA patients and normal fibroblasts with NHLRC2 knock-down and NHLRC2 overexpressing gene modifications. Transmission electron microscopy analysis of immortalized cell cultures from three FINCA patients demonstrated multilamellar bodies and distinctly organized vimentin filaments. Additionally, two of three cultures derived from patient skin biopsies contained cells that exhibited features characteristic of myofibroblasts. Altogether, the data presented in this study show for the first time that NHLRC2 is involved in cellular organization through regulation of the cytoskeleton and vesicle transport. We conclude that compound heterozygous p.Asp148Tyr and p.Arg201GlyfsTer6 mutations in NHLRC2 lead to severe tissue fibrosis in humans by enhancing the differentiation of fibroblasts to myofibroblasts.
Introduction
NHL repeat-containing protein 2 (NHLRC2) consists of a thioredoxin (Trx)-like domain and six NHL repeats (first identified in the NCL-1, HT2A and LIN-41 genes) (1) . The function of NHLRC2 is not known, however it is known that the Zinc Finger and ATHook Domain Containing (Zfat) protein, which is essential for T-cell homeostasis, is a transcription factor for NHLRC2 (2) , and NHLRC2 is cleaved by Caspase-8 during apoptosis (3) . The downregulation of NHLRC2 increased susceptibility of human colon cancer cells to ROS-induced apoptosis (3) . NHLRC2 has also been suggested as a novel serum biomarker for Alzheimer's disease (AD) (4) . Interestingly, knock-down (KD) of miR-155, which has been reported to be altered in the brain tissue of patients with AD, decreased the expression of NHLRC2 in mice (5) .
Recently, we reported that patients with compound heterozygous NHLRC2 mutations developed tissue fibrosis, neurodegeneration and cerebral angiomatosis (FINCA disease) (6) . Histopathological findings in the FINCA lungs resembled those of fibrotic non-specific interstitial pneumonia (6) . In addition, novel histopathological structures, termed 'granuloma-like lesions', were observed in the lungs of all FINCA patients (6) . These structures were significantly larger than typical granulomas in the lung and histologically distinct from the 'fibroblast foci' characteristic of idiopathic pulmonary fibrosis (IPF) (7) . The 'granuloma-like lesions' in FINCA patients were surrounded by hyaline-resembling extracellular material that contained large spindle-shaped cells, specifically myofibroblasts (6) .
Formation of fibrous connective tissue is vital for wound healing and tissue repair, yet it can occur to excess in devastating diseases and have a poor outcome, especially in cardiovascular and respiratory diseases (8) . The formation of excess fibrous connective tissue is defined as fibrosis or scarring when it occurs in response to injury. The initiating factor in pulmonary fibrosis is most likely damage to the alveolar epithelium which results in the activation and proliferation of fibroblasts and their differentiation to myofibroblasts that secrete greater amounts of extracellular matrix (ECM) proteins such as collagen that are characteristic of fibrosis (8, 9) . Fibrosis is a well-recognized cause of morbidity and mortality; however, the effects of chronic fibrosis cannot be reversed with current knowledge as the complexity of fibrosis is not fully understood (8) . Uncontrolled fibrosis leads to irreversible stiffening of the affected tissue and can cause organ malfunction and death (8) . Pathways with transforming growth factor-β (TGF-β) have been connected to fibrosis and inflammation (8, 9) . TGF-β1 induces the differentiation of fibroblasts to myofibroblasts, which have a higher activity for collagen production than fibroblasts (10) .
Dysfunction of NHLRC2 has not been described in association with any human disease other than FINCA disease, in which the patients harbor biallelic substitutions, p.Asp148Tyr, and a frameshift 2-bp deletion, p.Arg201GlyfsTer6, in the thioredoxinlike domain (6) .
Polymelia, conjoined twins and a wide range of neural tube related developmental malformations have been reported in the Angus cattle that are homozygous for a p.Val311Ala substitution in the beta-propeller domain of NHLRC2 (11) . This bovine syndrome is called 'Developmental Duplications' (DD) (OMIA 002103-9913) (12) . Fibrosis is not however reported in DD affected cattle, including those animals that survive to adulthood. In the mouse, Nhlrc2 truncating mutations are lethal in homozygotes before the E8.5 stage of embryogenesis (6, 13 ; https://www.ideals.illinois.edu/handle/2142/92824) and NHLRC2 seems to be crucial in the maintenance of multi-organ homeostasis (6) . The basic function of NHLRC2 is however unknown and no other molecule with a similar domain composition has been characterized to date. In the current work, we used immortalized fibroblast cultures from the skin of three patients with FINCA disease in combination with upto-date technologies, including clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene KD and proximitylabeling mass spectrometry (MS) [proximity-based biotinylation identification (BioID)], to reveal the first insights into the function of NHLRC2 at the cellular level. We show that the mutation in the Trx-like domain of NHLRC2 in FINCA patients lead to distinctly organized vimentin filaments and accumulation of multilamellar bodies (MLBs) in the cytoplasm. Our results indicate that NHLRC2 functions in cellular cytoskeleton organization and vesicle transport, through regulation of intermediate size filaments (IFs) and motor proteins. Furthermore, our data suggests that the compound heterozygous mutations of NHLRC2 in FINCA disease lead to severe tissue fibrosis by increasing the differentiation of fibroblasts to myofibroblasts.
Results

NHLRC2 is expressed in multiple cell types
The expression level of NHLRC2 was significantly decreased in skin fibroblasts from FINCA patients (see full analysis in our previous publication) (6) . Here, we analyzed several commercially available human cell lines to determine endogenous NHLRC2 expression levels. NHLRC2 (79 444 Da, isoform I) (14) was quantified in normal human dermal fibroblasts (NHDF), human skeletal myoblasts (HSkM), human embryonic kidney cells (HEK293), liver hepatocellular carcinoma cells (HepG2) and cervical cancer HeLa cells. All of these cell lines expressed NHLRC2, with the highest level in skeletal myoblasts, suggesting that NHLRC2 functions are required in various cell types ( Fig. 1A and B) . Furthermore, Medicalgenomics database (15, http://medicalgenomics.org/details_view_limited?gene_id= 374354#v) indicates that the highest expression of NHLRC2 is in the human heart and according to the Genevestigator human RNA expression data (16) , the highest expression of NHLRC2 is in cardiomyocytes (Supplementary Material, Fig. S1A and B) . This is consistent with our observation that even though fibrosis primarily manifest in the lungs of FINCA patients, one of the cases also had pathological findings associated with fibrosis in the heart (6).
We further analyzed the expression of Nhlrc2 in heterozygous Nhlrc2 tm1a null adult mice by beta-galactosidase staining of the heart, liver and lungs; the organs severely affected in FINCA patients. Occasional dotted positivity for expression was seen in heart tissue, apparently in cardiomyocytes of heterozygous Nhlrc2 tm1a mice (Supplementary Material, Fig. S2B ).
Positive staining was also seen in the liver but most of the hepatocytes seemed to have faint or negligible expression (Supplementary Material, Fig. S2D ). In addition, dotted positive staining was seen in some cells of the lung alveoli, whereas most of the type I pneumocytes forming the epithelial lining remained negative (Supplementary Material, Fig. S2F ). This data indicates that NHLRC2 is also expressed in tissues from adult mice in addition to developing mouse embryos (6) .
Soluble endogenous NHLRC2 is located in the cytosol
The subcellular localization of endogenous NHLRC2 was determined by fractionation of cultured control fibroblasts. The majority of NHLRC2 is located in the cytosol (Fig. 1C-D) . However, whether the mitochondria contain a small amount of NHLRC2 remains uncertain as the obtained mitochondrial fraction contained some cytoplasmic remnants of cytoskeletal tubulin. The endogenous NHLRC2 localized to the soluble fraction after the alkaline carbonate treatment, indicating that NHLRC2 resides in the cytosol in a soluble form (Fig. 1E) . Due to the lack of a specific antibody against endogenous NHLRC2 for immunocytochemistry, we created a stable fibroblast cell line expressing NHLRC2 with a C-terminal His-tag, and transiently transfected HEK293 cells to express NHLRC2 with a C-terminal c-myc-FLAG-tag. Immunocytochemistry confirmed the cytosolic localization of the tagged NHLRC2 ( Fig. 2A and B) . The immunostaining exhibited no co-localization between NHLRC2-His and the mitochondrial marker, TOM20 (Supplementary Material, Fig. S3A ).
NHLRC2 is suggested to interact in several cytosolic processes, including cell-cell adhesion, cell division and intracellular protein transport
BioID is a recent technique utilizing in vivo biotinylation to identify protein-protein interactions (17) . Here, we created a stable, human embryonic kidney (HEK) cell line expressing recombinant NHLRC2-BirA-FLAG that localized to the cytosol ( Fig. 2C) and had a functional C-terminal BirA-ligase (Supplementary Material, Fig. S4A ).
The BioID-MS data showed a broad range of interacting partners for NHLRC2, suggesting that NHLRC2 is involved in many biochemical pathways. High-confidence interaction partners were identified from 24 protein complexes, plus 53 proteins not annotated as being part of any complex (Fig. 3A) . To validate potential interaction of NHLRC2 with these proteins, EEF1G was chosen as a representative interacting protein.
Indeed, double staining of EEF1G and His-probe in fibroblasts expressing C-terminally His-tagged NHLRC2 revealed partial colocalization ( Fig. 2A) .
According to GO analysis, interactors of NHLRC2 in our HEK cell model are involved in a range of biological processes (BP) including cell-cell adhesion, cell division and intracellular protein transport when using a BP DIRECT gene ontology set (Fig. 3B , Table S1 ), as well as in the organization of cellular components, the cell cycle and macromolecule localization when using BP FAT gene ontology set (Supplementary Material, Table S1 ). Furthermore, the interactors identified resided mainly in the cytosol (Table S1 ), particularly in the vicinity of the plasma membrane and partially associated with exo-and endosomes (Fig. 3C ).
Distinct organization of intermediate filaments, MLBs and differentiation of myofibroblasts associated with FINCA disease-causing mutations in NHLRC2
Our previous histological analyses of lung biopsies and lung tissue samples taken at autopsy of FINCA patients showed fibrotic lungs and alveoli lined by hyperplastic epithelium consisting of type II pneumocytes with intracellular MLBs (6). MLBs are described as a subclass of lysosomes referred to as secretory lysosomes (18) . In lung type II alveolar cells, MLBs function as exocytotic secretory granules for surfactants (19) (20) (21) . At the surface of the alveolae, surfactants regulate surface tension at the air-cell interface and protect the alveola from collapse during respiration (22) . In this work, immortalized cells cultured from skin biopsies of FINCA patients were examined by TEM. Interestingly, in these skin derived cells, multiple intracellular MLBs were detected, as in type II pneumocytes of the FINCA patient (Fig. 4A) , but now in association with multivesicular bodies (MVBs) and distinctly organized intermediate size fibers (IFs) (approximately 10 nm in diameter) (Fig. 4B-C) . In the lung, MVBs are involved in trafficking surfactant protein B from the Golgi to the MLBs (18) . Further analysis of MLBs identified from immortalized cells grown from FINCA patient skin biopsies by immunoelectron microscopy (IEM) indicated the presence of Lysosome-associated membrane protein 1 (LAMP-1), suggesting that the MLB structures indeed, at least partly, originated from lysosomes ( Fig. 5A-B) . The IFs were recognized as vimentin by IEM ( Fig. 5C-D) . However, the immunostaining showed no colocalization between NHLRC2-His/c-Myc and LAMP1 or vimentin Two (patients 2 and 3) out of three cell cultures derived from FINCA patients' skin biopsies had clear myofibroblastic characteristics, such as intracellular actin bundles and extracellular fibronectin fibrils forming a fibronexus, which is the specific ultrastructural feature of the myofibroblast (Fig. 6A-B ) (23) . Immunocytochemistry and -blotting showed that the majority of these cells (>50-85%) were α-SMA positive, which further confirmed that they were myofibroblasts ( Fig. 6C-G) . One of the three FINCA patient skin-biopsy derived, immortalized cell cultures (patient 1) contained mainly fibroblasts rather than myofibroblasts according to α-SMA immunocytochemistry staining (Fig. 6D ).
NHLRC2 affects the expression of vimentin subtypes, cellular morphology and organization of subcellular organelles
The organized IFs were a dominant and prominent ultrastructural feature of cells cultured from FINCA patient skin biopsies. Overexpression, CRISPR-Cas9 KD and complementation Using lentiviral mediated gene transfer, stable overexpression of wild-type NHLRC2 (with/without His-tag) was generated in patient 1 skin biopsy-derived fibroblasts and in control fibroblasts, leading to a ∼50-fold increment in the expression level of NHLRC2 (Supplementary Material, Fig. S4C ). In addition, we silenced the expression of endogenous NHLRC2 in control fibroblasts by CRISPR/Cas9 (Supplementary Material, Fig. S4D ). Based on Sanger sequencing of the TOPO-TA-cloned PCR products, targeting exons 1 (by Cas9n) and 3 (by Sp-Cas9-HF1) of NHLRC2 led to the following compound heterozygous mutations, respectively, p.Pro4delfsTer21 and p.Thr30delins Leu-Gly-Arg-Gln-Arg-His-Asp-Asn-His-Leu-Asn-Gln-Asp-Val- Table S1 ).
Glu-Val-Ala-Val-Ser-Gln-Asp-His-Thr-Thr-Thr-Leu-Gln-Pro-ArgTer60 (KD1), p.Cys139 Arg150delfsTer176 and p.Asp150Gly (KD2). These two mutant clones, which were utilized for further experiments, had ∼20% and ∼40% residual NHLRC2 protein expression. Decreased expression of NHLRC2 led to a clear change in cell morphology, causing a spherical shape and a less co-directional growth pattern (Fig. 7A ). In addition, subcellular organelles resided mainly on one side of the cell, suggesting that their organization was affected by KD of NHLRC2 (Fig. 7B ). The KD1 cell line also manifested a tendency to grow multiple protrusions that were positive for vimentin (Fig. 7C) .
We then further studied the expression of vimentin in these cell lines. Interestingly, in addition to subtype I (46 kD), vimentin subtypes III (50 kD) and IV (54 kD) (24) were present in patient fibroblasts but were not observed when cell cultures were complemented with the wild-type NHLRC2 (Fig. 7D ). In addition, vimentin subtypes III and IV emerged in KD1 cells, suggesting that decrease in the level of NHLRC2 expression results in the appearance of lower molecular-sized subtypes of vimentin with presumably distinct fibrillar organization detected by TEM. Furthermore, immunoblotting of the control fibroblasts modified to overexpress NHLRC2 showed a significant reduction in the level of vimentin subtype I, without the presence of any other vimentin subtypes, further suggesting an association between regulation of the expression levels of NHLRC2 and vimentin (Fig. 7D) .
Likewise, the induction of recombinant NHLRC2-BirA-FLAG by tetracycline led to a ∼40% decrease in vimentin levels (Fig. 7D) , which was taken manually into account when analyzing the BioID-MS data (Supplementary Material, Table S1 ). (Vimentin was detected by MS in each experimental replicate.)
In addition, fewer MLBs were observed via TEM after complementation of FINCA patient fibroblasts with the wild-type NHLRC2, suggesting that these structures were associated with dysfunction of NHLRC2. However, MLBs and MVBs with variable sizes were also seen in some of the patient cells even after the complementation, which may reflect the different expression levels of the wild-type NHLRC2 in these single cells as the NHLRC2 gene was randomly inserted via lentiviral gene transfer throughout the whole genome of the immortalized, patientderived fibroblasts.
Dysfunction of NHLRC2 leads to altered expression of IFs, IL-1β and Kinesin light chain 1
Next, we analyzed the mRNA expression of other IF proteins by quantitative polymerase chain reaction (qPCR), including the keratin KRT17, because of its previous connection to cytoskeletal regulation via eukaryotic translation elongation factor 1 gamma (EEF1G), and the most abundant keratin, KRT18 (25) . Patient 1-derived fibroblasts had increased expression levels of both KRT17 and 18, which were significantly decreased after complementation with wild-type NHLRC2. Patient 2-derived cells (a mixture of fibro-and myofibroblasts) exhibited increased expression of KRT17 (Fig. 8A) . The overexpression of NHLRC2 in control fibroblasts led to a significant decrease in the expression of KRT17 and KRT18 compared with the original fibroblasts, by qPCR (Fig. 8B) . Altogether, this data suggests that changes in the expression of NHLRC2 affect the expression of KRT17 and KRT18.
In addition, COL1A1 and COL1A2 were analyzed from cell lines overexpressing NHLRC2, given the role of collagens in fibrosis (8) , and IL-1β, LCN2 and VEGFA based on their connection to inflammation (26) (27) (28) . From all the genes analyzed, only the expression of IL-1β significantly decreased in the cell lines overexpressing NHLRC2 (Fig. 8B ). In addition, the expression of TGF-β1, which has been broadly associated with differentiation of myofibroblasts, was studied (8, 9) . According to immunoblotting, patient 1 had a significantly decreased expression level of inactive TGF-β1 compared to the control (P < 0.009). After complementation with NHLRC2, the expression level of inactive TGF-β1 increased significantly (P < 0.038, compared with the patient-derived fibroblasts before complementation), reaching the normal expression levels of the control (Fig. 8C and D) .
Motor proteins have a key role in connecting the cell cytoskeleton and vesicle transport. To further examine whether NHLRC2 dysfunction could cause alterations in motor proteins such as dynein, myosin or kinesin, we investigated their expression levels in fibroblasts from FINCA patient 1 before and after the NHLRC2 complementation (Fig. 8C) . The amount of myosin heavy chain 10 (MYH10) remained stable despite NHLRC2 complementation, but levels of dynein cytoplasmic 1 heavy chain 1 (DYNC1H1) and Kinesin light chain 1 (KLC1) changed significantly in patient 1 fibroblasts after NHLRC2 complementation (Fig. 8D) .
Discussion
Mutations in NHLRC2 were identified in association with severe fibrosis in the lungs of patients with FINCA disease (6) . Disruptions during normal wound repair contribute to the development of tissue fibrosis (29) . After tissue injury, epithelial cells release inflammatory mediators, which trigger platelet activation, followed by the appearance of leukocytes secreting profibrotic cytokines, such as IL-1β, TNF, IL-13 and TGF-β1 (26, 30, 31) . Next, fibroblasts proliferate and differentiate into α-SMA-expressing myofibroblasts, which release ECM components. Thus, myofibroblasts have a well-established role in the pathogenesis of fibrosis in several tissues, including the lungs (26), liver (30) and heart (31) . As myofibroblasts are important in excessive or ongoing fibrosis (32), the key question in fibrosis could be about what factors regulate the differentiation of fibroblasts to myofibroblasts. In our studies, overexpression of wild-type NHLRC2 in control fibroblasts led to a significant decrease in the expression level of IL-1β mRNA. Furthermore, overexpression of wild-type NHLRC2 in patientderived fibroblasts led to an increase in the level of inactive TGF-β1, which, together with IL-1β expression, is another key factor in the induction of myofibroblast differentiation (29) . Finally, two out of three cell cultures derived from FINCA patients' skin biopsies differentiated into α-SMA-expressing myofibroblasts under normal cell culture conditions. The differences between these FINCA patient-derived cell lines could reflect phenotypic variation caused by other genetic factors specifically involved in the regulation of myofibroblast differentiation. In the future, identification of patients from other ethnic backgrounds with pathogenic NHLRC2 variants may shed more light on the possible phenotypic variation between cases with identical NHLRC2 dysfunction. Interestingly, two GWAS studies have previously listed NHLRC2 as a differentially expressed gene when comparing rapidly and slowly progressing IPF patients (33) and in association with decreased lung function values (34) . Now, our observations suggest for the first time that NHLRC2 is involved in regulating the differentiation of fibroblasts to myofibroblasts, and that the dysfunction of NHLRC2 can lead to severe tissue fibrosis in humans. The inflammatory response often leads to fibrosis as the profibrotic cytokines affect myofibroblast differentiation (26, (29) (30) (31) . NHLRC2 has been previously associated with inflammation in an equine model of chronic asthma, where NHLRC2 expression increased under inflammation (35) . Furthermore, Zfat has been shown to regulate the expression of NHLRC2 in thymocytes, which are the precursors of T lymphocytes that function in the cell-mediated immune response (2) . The IL-1 cytokine family is recognized as a key mediator of inflammation. The accumulation of IL-1β occurs under the control of the NLRP3 inflammasome complex (28) , which is in turn activated by vimentin (36) . Indeed, the role of vimentin with respect to fibrosis is fascinating. Vimentin filaments have been shown to bind and stabilize collagen mRNAs, which is the predominant mechanism for high collagen expression in fibrosis (37) . In our study, the low expression of mutant NHLRC2 led to an increased expression of several subtypes of vimentin filaments. Notably, these subtypes have been previously demonstrated to emerge under different osmotic stress conditions, forming a similar, strong filamentous network (24) . Altogether, changes in cytoskeletal organization, especially in vimentin organization, were clearly detectable in our several independent cell line approaches affected by either loss of function or upregulation of NHLRC2. In addition, the overexpression of NHLRC2 resulted in decreased expression levels of vimentin and IL-1β, suggesting that the mechanism by which NHLRC2 could be involved in fibrogenesis is through regulation of an inflammatory pathway.
As our cell cultures were not supplemented with vitamin C, we are not able to state whether or not there is an increase in the deposition of ECM components such as collagen fibrils by the myofibroblast-like cells cultured from the skin of FINCA patients. In this context, it is however interesting to note that hypertrophic scarring was not reported in the skin of FINCA patients (6) .
EEF1G functions in the enzymatic delivery of aminoacyl tRNAs to the ribosome, however it has also been shown to have a role in cytoskeletal regulation (25, 38) . EEF1G interacts with keratins, particularly with KRT17, and there is also evidence that binds to the promoter region of vimentin, targeting the vimentin mRNA to the appropriate cellular compartment for translation (25, (38) (39) (40) (41) . Here, our studies showed that NHLRC2 partly co-localized and interacted with EEF1G, as indicated by our proximity labeling MS and immunocytochemistry results. The expression levels of KRT17, KRT18 and IL-1β were significantly decreased in the control fibroblasts overexpressing (OE) NHLRC2 (with and without His-tag) by qPCR analysis, (C) immunoblotting of control (C), patient (P1) and NHLRC2 complementation of patient 1-derived fibroblasts (Pcomp) by motor protein antibodies and TGF-β1, (D) P-values from the Image J quantitation of motor protein and TGF-β1 immunoblotting. Abbreviations: C, control; P, patient; Pcomp, patient-derived fibroblasts complemented with NHLRC2; OE, overexpression; OE His-tag, overexpression with C-terminal histidine tag. Anti-DYNC1H1 (Santa Cruz Biotech., sc-514579, Dallas, Texas, USA), anti-MYH10 (Santa Cruz Biotech., sc-376942, Dallas, Texas, USA), anti-KLC1 (Santa Cruz Biotech., sc-58776, Dallas, Texas, USA), anti-TGFβ (Abcam, ab92486, Cambridge, UK), anti-GAPDH (Genetex, GTX100118, Irvine, CA, USA). (↓ downregulation, ↑ upregulation, n.s. not statistically significant, ↑ equivalent of * P < 0.05, ↑↑ equivalent of * * P < 0.01, ↑↑↑ equivalent of * * * P < 0.001).
Furthermore, the expression of KRT17 and KRT18 increased with dysfunction of NHLRC2, raising the possibility that NHLRC2 regulates intermediate filaments (IFs) through direct interaction with EEF1G.
The downregulation of NHLRC2 by CRISPR-Cas9 led to alterations in general cell morphology and subcellular organization of cells, possibly implicating defective nuclear positioning. Actin filaments, microtubules and associated motor proteins have been described as the principal cytoskeletal elements behind the organization of cellular components, like nuclear positioning (42) . Indeed, our proximity labeling MS identified putative interactors for NHLRC2 from BPs such as the organization of cellular components and the cytoskeleton. We also detected an accumulation of Lamp1-positive MLBs by IEM/TEM in FINCA patient-derived fibro-/myofibroblasts, although the most dominant morphological feature of these patient cells was the organized vimentin IFs that were no longer observed after complementation with full-length NHLRC2, based on TEM and immunoblotting. The spatial organization of cellular components is closely connected to the cytoskeleton through motor proteins. In this study, the association of the motor protein DYNC1H1 with NHLRC2 was confirmed by NHLRC2 complementation studies. DYNC1H1 is involved in the dyneindynactin complex and regulates lysosomal transport (43) . Our observations suggest that the accumulation of LAMP-1 positive MLBs and MVBs in the cytoplasm of cells cultured from the skin of FINCA patients may be the result of lysosomal transport defects arising from NHLRC2 dysfunction. Interestingly, the accumulation of MLBs has previously been connected to galactosidase and sialidase defects in lysosomal storage diseases (44) (45) (46) (47) and autophagy (18, 44) . MLBs have also been reported to increase in skin fibroblasts cultured from Rett Syndrome (RTT) patients, a neurodevelopmental disorder with oxidative stress imbalance as a key phenotypical feature-these RTT fibroblasts with MLBs had signs of redox imbalance (48) .
The development of tissue fibrosis is complex and at present not fully understood. In this study, several common factors that have an established role in fibrogenesis were affected by NHLRC2. However, certain unique histopathological characters, such as 'granuloma-like lesions' discovered in FINCA lungs, rather than usual 'fibroblast foci' seen in IPF, imply that dysfunction of NHLRC2 caused by the FINCA mutations adds a novel aspect to the underlying mechanism of fibrosis by affecting the differentiation of fibroblasts to myofibroblasts. Based on our observations, we suggest that NHLRC2 functions in cellular organization through regulation of the cytoskeleton and enhances tissue fibrosis by affecting vimentin IFs, vesicle transportation and pro-inflammatory regulators, enhancing the differentiation of fibroblasts to myofibroblasts.
Materials and Methods
Informed consent
The Ethics Committee of the Northern Ostrobothnia Hospital District (Oulu, Finland) has approved the study protocol and it is in compliance with the Helsinki Declaration of 1975, as revised in 2000. Written informed consent was obtained from the guardians of the patients whose samples were included in the study. Each of the three patients manifested with the same genophenotype with heterocompound c.G442 T and c.601 602del mutations in NHLRC2 leading to amino acid substitutions p.Asp148Tyr and p.R201GfsTer6. The patients are referred to as in our previous publication (6).
Immunoblotting. Twenty micrograms of protein were loaded onto 4-20% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel (Precise protein gel #25244, Thermo Fisher Scientific, Waltham, MA, USA). Western blotting was performed with a standard protocol using the primary antibodies specified in each figure legend. The secondary antibodies used were Goat pAb to RRb IgG horseradish peroxide (HRP) (Abcam, Cambridge, UK) and Goat Anti-Mouse IgG H&L (HRP) (Abcam, Cambridge, UK). A Westernbright TM ECL kit (K-12045-D20, Advansta, Menlo Park, CA, USA) was used for detection.
Subcellular fractionation.
The subcellular localization of endogenous NHLRC2 was studied in control fibroblasts. The nuclear fractionation was made by a rapid, efficient and practical (REAP) method as described previously (49) . The subcellular fractionation of other organelles included the isolation of cytosolic, endoplasmic reticulum, lysosomal and mitochondrial fractions. Altogether 2 × 10 8 control fibroblasts were washed twice with phosphate-buffered saline (PBS), trypsinized and collected by centrifugation at 600 × g for 5 min at 4
• C. The pellet was then suspended in ice-cold buffer (225 mM mannitol, 75 mM sucrose, 0.1 mM EGTA and 30 mM Tris-HCl pH 7.4) and homogenized 10× at 600 rpm on ice using a glass/Teflon Potter Elvehjem homogenizer. The fractionation was carried out as described elsewhere (50) .
Alkaline carbonate extraction. To determine whether NHLRC2 is associated with membranes, 7 × 10 6 control and patient fibroblasts were extracted in 100 μl sodium carbonate, pH 11.5, for 30 min on ice. Half of the extracted volume was saved for immunoblot analysis ('input' fraction), while the other half was centrifuged at 20 000 × g for 1 h at 4
• C. The resulting supernatant ('soluble') fraction and pellet ('membrane') fraction were analyzed by immunoblotting.
LacZ staining. X-gal staining was undertaken on the lung, liver and heart from two-month old heterozygous C57BL/6N-A tm1Brd Nhlrc2 tm1a(KOMP)Wtsi /WtsiOulu mice obtained from the Infrafrontier-the European Mouse Mutant Archive (EMMA) repository (strain number EM:10219) (51, 52) . In this mouse model, the gene trap cassette, including LacZ, is inserted within the NHLRC2 gene. The beta-galactosidase staining detects the cell types where this specific gene region is actively expressed.
Cell culture. The patient-derived skin fibroblast cultures were established according to a previous method (53) . The control and patient fibroblast cells were immortalized by a retroviral vector that expresses the E7 gene of type 16 human papilloma virus and a retroviral vector that expresses the protein component of human telomerase (54) Cloning and generation of stable cell pools to express recombinant NHLRC2-BirA-FLAG protein. NHLRC2 was C-terminally tagged with BirA-FLAG via Gateway cloning into a pcDNA5-BirA-FLAG-C-ter plasmid. Stable cells were generated as Flp-In 293 T-REx cell pools (Invitrogen, Carlsbad, CA, USA) and the expression of recombinant protein was induced for 24 h with tetracycline (1 μg/ml) as described (55) . For BioID experiments, the cells were treated with 50 μM biotin for 24 h in combination with tetracycline. The level of tetracyclineinduced expression of NHLRC2-BirA-FLAG was analyzed from three separate samples by immunoblotting with anti-NHLRC2 (Novusbio, Littleton, CO, USA Biotinylation identification and MS. BioID purifications were carried out by thawing the cell pellet in 3 ml of ice-cold lysis buffer (0.5% IGEPAL, 50 mM Hepes, pH 8.0, 150 mM NaCl, 50 mM NaF, 1.5 mM NaVO3, 5 mM EDTA, 0.1% SDS, 1 mM DTT, 1 mM PMSF, supplemented by protease inhibitors; Sigma-Aldrich, Saint Louis, MI, USA). Lysates were treated with benzonase and sonicated. Centrifugation at 16 000 × g was conducted to obtain cleared lysate, and the lysate was then loaded onto spin columns (Bio-Rad Hercules, CA, USA) containing 200 μl Strep-Tactin beads (IBA, GmbH) pre-washed with wash buffer 1 (0.5% IGEPAL, 50 mM Hepes, pH 8.0, 150 mM NaCl, 50 mM NaF, 1.5 mM NaVO3, 1 mM DTT, 5 mM EDTA, 0.5 mM PMSF with protease inhibitors; SigmaAldrich, Saint Louis, MI, USA). The beads were washed with 3 × 1 ml wash buffer 1, and 4 × 1 ml with wash buffer 2 (50 mM Hepes, pH 8.0, 150 mM NaCl, 50 mM NaF, 5 mM EDTA). After the final wash, the beads were resuspended in 2 × 300 μl elution buffer (50 mM Hepes, pH 8.0, 150 mM NaCl, 50 mM NaF, 5 mM EDTA, 0.5 mM Biotin) for 5 min. Eluates were collected in Eppendorf tubes, followed by a reduction of the disulfide bonds with 5 mM Tris (2-carboxyethyl) phosphine for 30 min at 37
• C and alkylation with 10 mm iodoacetamide. The proteins were then digested to peptides with sequencing grade modified trypsin (Promega, Madison, WI, USA, #V5113) at 37
• C overnight.
After quenching with 10% TFA, the samples were desalted by C18 reversed-phase spin columns according to the manufacturer's instructions (Harvard Apparatus, Cambridge, MA, USA).
The eluted peptide sample was dried in a vacuum centrifuge and reconstituted to a final volume of 30 μl in 0.1% TFA and 1% CH 3 CN. and common contaminants. Cysteine carbamidomethylation was set as a fixed modification, while methionine oxidation, acetylation of protein N-terminus and phosphorylation of serines, tyrosines and threonines were included as variable modifications. Trypsin was designated as the digestion enzyme, with a maximum of two missed cleavages allowed. A minimum peptide length of 7 was set for the search, with a false discovery rate of 5% at the peptide and protein levels. The match-betweenruns option was selected to identify peptides across runs based on retention time and the mass-to-charge ratio. The MaxLFQ algorithm was utilized for label-free protein quantification (57, 58) . For filtering, the Contaminant Repository for Affinity Purification (CRAPome, http://www.crapome.org/) was used.
Liquid chromatography-MS (LC-MS
Identified proteins with an occurrence of 20% or more in CRAPome (59) were discarded, unless their spectral counts were at least 3× higher than the CRAPome average. Proteins identified in <75% of the MS runs were discarded, as were those identified with an average spectral count of less than two. GO analysis of the identified prey proteins was conducted with the DAVID gene functional analysis tool using the GO BP DIRECT, GO CC DIRECT, GO BP FAT and GO CC FAT gene ontology sets. Cloning to generate NHLRC2 KD cell lines. NHLRC2 KD cell lines were generated using CRISPR/Cas9 nucleases (62) into LentiCRISPR v2 plasmid (#52961, Addgene, Cambridge, MA, USA). E-CRISP-Version 5.1 program (Boutros lab, Deutsches Krebsforschungszentrum, Germany, http://www.e-crisp.org/E-CRISP/) was used to generate the target site in NHLRC2 exons 1 and 3. For target sites in exon 1, a nickaseCas9 (Cas9n, D10A) was used (#63593, Addgene, Cambridge, MA, USA). For target sites in exon 3, a high-fidelity CRISPR/Cas9 nuclease (Sp-Cas9-HF1) was cloned from VP12 (#72247, Addgene Cambridge, MA, USA) into LentiCRISPR v2 plasmid (63) . The gRNA oligo with BsmBI (New England Biolabs) overhangs were subcloned into the LentiCRISPR v2 plasmid and then used for lentivirus preparation. In addition, two separate fibroblast control lines were used for the NHLRC2 KD generation in exons 1 and 3. The resultant genetic editing of NHLRC2 KD cells by CRISPR/Cas9 was verified by TOPO PCR cloning (Thermo Scientific, Waltham, MA, USA) and Sanger sequencing.
Cloning for NHLRC2 overexpression cell lines. The NHLRC2 overexpression cell lines were made with the Gateway cloning system (Thermo Fisher Scientific, Waltham, MA, USA) using the pDONR221 entry vector and pLenti CMV puro DEST (w118-1) (#17452, Addgene, Cambridge, MA, USA) plasmids according to the manufacturer's instructions. The patient NHLRC2 complementation was conducted with the same primers that were used to generate the overexpression cell line.
Lentiviral gene transfer.
The functional studies were performed using immortalized control fibroblasts and immortalized fibroblast cells established from NHLRC2-deprived (FINCA) patients 1 and 2 (64). The lentiviruses were produced by culturing 
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